These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 24946157)

  • 1. Molecular testing for the BRCA1 and BRCA2 Ashkenazi Jewish founder mutations: a report on the College of American Pathologists proficiency testing surveys.
    Tafe LJ; Datto MB; Palomaki GE; Lacbawan FL;
    Genet Med; 2015 Jan; 17(1):58-62. PubMed ID: 24946157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Results of the College of American Pathology/American College of Medical Genetics and Genomics external proficiency testing from 2006 to 2013 for three conditions prevalent in the Ashkenazi Jewish population.
    Feldman GL; Schrijver I; Lyon E; Palomaki GE;
    Genet Med; 2014 Sep; 16(9):695-702. PubMed ID: 24577267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic Predisposition to Breast Cancer Due to Mutations Other Than BRCA1 and BRCA2 Founder Alleles Among Ashkenazi Jewish Women.
    Walsh T; Mandell JB; Norquist BM; Casadei S; Gulsuner S; Lee MK; King MC
    JAMA Oncol; 2017 Dec; 3(12):1647-1653. PubMed ID: 28727877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular genetic testing for cystic fibrosis: laboratory performance on the College of American Pathologists external proficiency surveys.
    Lyon E; Schrijver I; Weck KE; Ferreira-Gonzalez A; Richards CS; Palomaki GE;
    Genet Med; 2015 Mar; 17(3):219-25. PubMed ID: 25077647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multigene panels in Ashkenazi Jewish patients yield high rates of actionable mutations in multiple non-BRCA cancer-associated genes.
    Frey MK; Sandler G; Sobolev R; Kim SH; Chambers R; Bassett RY; Martineau J; Sapra KJ; Boyd L; Curtin JP; Pothuri B; Blank SV
    Gynecol Oncol; 2017 Jul; 146(1):123-128. PubMed ID: 28495237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. To reflex or not: additional BRCA1/2 testing in Ashkenazi Jewish individuals without founder mutations.
    Petrucelli N; Mange S; Fulbright JL; Dohany L; Zakalik D; Duquette D
    J Genet Couns; 2015 Apr; 24(2):285-93. PubMed ID: 25199548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRCA1 and BRCA2 founder mutations and the risk of colorectal cancer.
    Niell BL; Rennert G; Bonner JD; Almog R; Tomsho LP; Gruber SB
    J Natl Cancer Inst; 2004 Jan; 96(1):15-21. PubMed ID: 14709734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frequency of BRCA1 and BRCA2 mutations in unselected Ashkenazi Jewish patients with colorectal cancer.
    Kirchhoff T; Satagopan JM; Kauff ND; Huang H; Kolachana P; Palmer C; Rapaport H; Nafa K; Ellis NA; Offit K
    J Natl Cancer Inst; 2004 Jan; 96(1):68-70. PubMed ID: 14709740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews.
    Hartge P; Struewing JP; Wacholder S; Brody LC; Tucker MA
    Am J Hum Genet; 1999 Apr; 64(4):963-70. PubMed ID: 10090881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Founder mutations in BRCA1/2 are not frequent in Canadian Ashkenazi Jewish men with prostate cancer.
    Hamel N; Kotar K; Foulkes WD
    BMC Med Genet; 2003 Aug; 4():7. PubMed ID: 12911837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer.
    Moslehi R; Chu W; Karlan B; Fishman D; Risch H; Fields A; Smotkin D; Ben-David Y; Rosenblatt J; Russo D; Schwartz P; Tung N; Warner E; Rosen B; Friedman J; Brunet JS; Narod SA
    Am J Hum Genet; 2000 Apr; 66(4):1259-72. PubMed ID: 10739756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma.
    Ferrone CR; Levine DA; Tang LH; Allen PJ; Jarnagin W; Brennan MF; Offit K; Robson ME
    J Clin Oncol; 2009 Jan; 27(3):433-8. PubMed ID: 19064968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of nonfounder BRCA1/2 mutations in Ashkenazi Jewish patients presenting for genetic testing at a hereditary breast and ovarian cancer center.
    Frey MK; Kopparam RV; Ni Zhou Z; Fields JC; Buskwofie A; Carlson AD; Caputo T; Holcomb K; Chapman-Davis E
    Cancer; 2019 Mar; 125(5):690-697. PubMed ID: 30480775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence of BRCA1 and BRCA2 non-founder mutations in patients of Ashkenazi Jewish ancestry.
    Rosenthal E; Moyes K; Arnell C; Evans B; Wenstrup RJ
    Breast Cancer Res Treat; 2015 Jan; 149(1):223-7. PubMed ID: 25476495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
    Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
    Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2.
    Roa BB; Boyd AA; Volcik K; Richards CS
    Nat Genet; 1996 Oct; 14(2):185-7. PubMed ID: 8841191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of educational print materials on knowledge, attitudes, and interest in BRCA1/BRCA2: testing among Ashkenazi Jewish women.
    Schwartz MD; Benkendorf J; Lerman C; Isaacs C; Ryan-Robertson A; Johnson L
    Cancer; 2001 Aug; 92(4):932-40. PubMed ID: 11550168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recurrent germline mutations in BRCA1 and BRCA2 genes in high risk families in Israel.
    Laitman Y; Simeonov M; Herskovitz L; Kushnir A; Shimon-Paluch S; Kaufman B; Zidan J; Friedman E
    Breast Cancer Res Treat; 2012 Jun; 133(3):1153-7. PubMed ID: 22399190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hereditary cancer screening: Case reports and review of literature on ten Ashkenazi Jewish founder mutations.
    Cox DM; Nelson KL; Clytone M; Collins DL
    Mol Genet Genomic Med; 2018 Nov; 6(6):1236-1242. PubMed ID: 30152102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families.
    Levy-Lahad E; Catane R; Eisenberg S; Kaufman B; Hornreich G; Lishinsky E; Shohat M; Weber BL; Beller U; Lahad A; Halle D
    Am J Hum Genet; 1997 May; 60(5):1059-67. PubMed ID: 9150153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.